{
    "nctId": "NCT02970773",
    "officialTitle": "Prospective, Non-randomized, Open-label, Mono-centric, Cohort Study on the Absorption of Oral Rivaroxaban in Patients With a Cervical Spinal Cord Injury",
    "inclusionCriteria": "* Motor complete tetraplegia for at least 3 months\n* Age from 18 to 74 years\n* Body mass index (BMI) from 18 to 35kg/m2\n* Informed consent as documented by signature\n* Must have minimum age of 18 Years\n* Must have maximum age of 74 Years",
    "exclusionCriteria": "* Any anti-coagulation therapy (apart from rivaroxaban for second objective)\n* Hypersensitivity or allergy to factor Xa inhibitors\n* Acute bacterial endocarditis\n* Bleeding disorder\n* Clinically relevant active bleeding\n* Gastrointestinal ulcer or tumor\n* Hepatic dysfunction with increased bleeding risk\n* Renal failure / patients undergoing dialysis\n* Pregnancy and breast feeding\n* Gastrectomy, biliopancreatic diversion, resection or re-routing of small intestines\n* Feeding tube\n* Recent blood donation\n* Abnormalities of laboratory values: alanine-aminotransferase (ALAT), aspartate-aminotransferase (ASAT), gamma-glutamyl transferase (gammaGT), alkalic phosphatase (AP), bilirubin, amylase, lipase, cystatin C, creatinine, white blood cell count, haemoglobin, platelet count, prothrombin time, aPTT, fibrinogen, thrombin time, factors II,V,VII and X\n* Use of therapeutic or recreational drugs influencing plasmatic coagulation"
}